Pioglitazone Reduces Peritoneal Fibrosis via Inhibition of TGF-β, MMP-2, and MMP-9 in a Model of Encapsulating Peritoneal Sclerosis

REFERENCES

• Plum J, Hermann S, Fussholler A, . Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int. 2001;59(Suppl. 78):S42–S47.
   Google Scholar
• Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int. 1999;55:341–356.
   PubMed Web of Science ®Google Scholar
• Douvdevani A, Rapoport J, Konforty A, Argov S, Ovnat A, Chaimovitz C. Human peritoneal mesothelial cells synthesize IL-1 alpha and beta. Kidney Int. 1994;46:993–1001.
   PubMed Web of Science ®Google Scholar
• Offner FA, Feichtinger H, Stadlmann S, . Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol. 1996;148:1679–1688.
   PubMed Web of Science ®Google Scholar
• Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int. 2002;61:570–578.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Spiegelman BM. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev. 1995;5:571–576.
   PubMed Web of Science ®Google Scholar
• Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5(8):2145–2154.
   PubMed Web of Science ®Google Scholar
• Czoski-Murray C, Warren E, Chilcott J, . Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: A systematic review and economic evaluation. Health Technol Assess. 2004;8:1–91.
   Web of Science ®Google Scholar
• Ghosh AK, Bhattacharyya S, Lakos G, Mori Y, Chen S-J, Varga J. Peroxisome proliferator-activated receptor-γ signaling and profibrotic responses in normal skin disrupts TGF-β fibroblasts. Arthritis Rheum. 2004;50:1305–1318.
   PubMed Web of Science ®Google Scholar
• Zheng F, Fornoni A, Elliot SJ, . Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation. Am J Physiol Renal Physiol. 2002;282:F639–F648.
   Web of Science ®Google Scholar
• Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20:4699–4707.
   PubMed Web of Science ®Google Scholar
• Shinzato T, Ohya Y, Nakamoto M, Ishida A, Takishita S. Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats. Hypertens Res. 2007;30(9):863–873.
   PubMed Web of Science ®Google Scholar
• Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol. 2005;16(3):638–645.
   PubMed Web of Science ®Google Scholar
• Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2004;315(1):187–195.
   PubMed Web of Science ®Google Scholar
• Dong FQ, Li H, Cai WM, . Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (Engl). 2004;117(7):1040–1044.
   PubMed Web of Science ®Google Scholar
• Hoff CM. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(Suppl. 4):S57–S66.
   Google Scholar
• Sarioglu S, Sis B, Celik A, . Quantitative digital histochemistry with methenamine silver staining in renal allograft biopsies excluding pure chronic allograft nephropathy cases. Transplant Proc. 2006;38(2):490–491.
   PubMed Web of Science ®Google Scholar
• Williams JD, Craig KJ, Topley N, . Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–479.
   PubMed Web of Science ®Google Scholar
• Heimburger O, Waniewski J, Werynski A, . Periton transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 1990;38(39):495–506.
   PubMed Web of Science ®Google Scholar
• Io H, Ro Y, Tomino Y, . Morphological changes of peritoneum and expression of VEGF in encapsulated sclerosis rat models. Kidney Int. 2004;65:1927–1936.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Yang X, Zhang YJ, . Peroxisome proliferator-activated receptor-gamma is expressed by rat peritoneal mesothelial cells: Its potential role in peritoneal cavity local defense. Am J Nephrol. 2006;26:602–611.
   PubMed Web of Science ®Google Scholar
• Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J, Lindholm B. Inhibitive effect of troglitazone on TGF-beta(1) and fibronectin expression in human peritoneal mesothelial cells. Clin Nephrol. 2007;68(5):295–301.
   PubMed Web of Science ®Google Scholar
• Bozkurt D, Taşkın H, Sezak M, . Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model. Adv Perit Dial. 2008;24:32–38.
   PubMedGoogle Scholar
• Woessner FJ. MMPs and TIMPs: An historical perspective. Mol Biotechnol. 2002;22(1):33–49.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Li JJ, Kim KS, . High glucose decreases collagenase expression and increases TIMP expression in cultured human peritoneal mesothelial cells. Nephrol Dial Transplant. 2008;23:534–541.
   PubMed Web of Science ®Google Scholar
• Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-b1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol. 2001;12:2029–2039.
   PubMed Web of Science ®Google Scholar